Arrowstreet Capital Limited Partnership Cuts Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Arrowstreet Capital Limited Partnership decreased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 86.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,453 shares of the company's stock after selling 139,190 shares during the period. Arrowstreet Capital Limited Partnership's holdings in Kiniksa Pharmaceuticals were worth $444,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $158,000. China Universal Asset Management Co. Ltd. lifted its stake in Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Teacher Retirement System of Texas boosted its position in Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after buying an additional 719 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at about $258,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock worth $302,000 after buying an additional 1,680 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Insider Activity

In other news, CFO Mark Ragosa sold 36,372 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total value of $809,277.00. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at $510,815.50. This trade represents a 61.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,766 shares of company stock valued at $2,002,135. Corporate insiders own 54.57% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on KNSA. Wedbush restated an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Wednesday. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Trading Down 1.6 %

NASDAQ KNSA traded down $0.32 on Friday, hitting $20.21. The company's stock had a trading volume of 529,238 shares, compared to its average volume of 462,946. The firm has a market cap of $1.47 billion, a P/E ratio of -144.35 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15. The company's 50-day simple moving average is $21.05 and its 200 day simple moving average is $21.49.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million during the quarter, compared to analysts' expectations of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business's revenue was up 46.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.35 EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.